Last reviewed · How we verify
NCT03976206
Very Small Embryonic-like Stem Cells for Facial Skin Antiaging
Phase 1, PHASE2 trial testing Very small embryonic-like stem cell in Stem Cell Transplant Complications. Withdrawn.
20 May 2020
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Start date | 6 July 2019 |
| Primary completion | 20 May 2020 |
| Estimated completion | 1 July 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Very small embryonic-like stem cell — full drug profile →
Conditions studied
- Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →
- Skin Inflammation — all drugs for Skin Inflammation →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Adults 40 to 60, any sex, with Stem Cell Transplant Complications or Skin Inflammation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is the safety and efficacy of autologous very small embryonic-like stem cells(VSELs) to facial skin antiaging.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03976206
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Stem Cell Transplant Complications
Currently open trials in the same condition.
- NCT07509749 — Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease) · Phase 2 · recruiting
- NCT07340723 — Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) · Phase 2 · recruiting
- NCT06541002 — A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors · NA · recruiting
- NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting
- NCT06512545 — Modified Second Haplo-transplantation for Graft Failure · NA · recruiting
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
- NCT03973021 — Very Small Embryonic-like Stem Cells for Erectile Dysfunction · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03976206 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 19 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03976206.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing